These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 7579499)

  • 1. The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases.
    Quénel N; Wafflart J; Bonichon F; de Mascarel I; Trojani M; Durand M; Avril A; Coindre JM
    Breast Cancer Res Treat; 1995 Sep; 35(3):283-91. PubMed ID: 7579499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.
    Reed W; Hannisdal E; Boehler PJ; Gundersen S; Host H; Marthin J
    Cancer; 2000 Feb; 88(4):804-13. PubMed ID: 10679650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol.
    Hartmann LC; Ingle JN; Wold LE; Farr GH; Grill JP; Su JQ; Maihle NJ; Krook JE; Witzig TE; Roche PC
    Cancer; 1994 Dec; 74(11):2956-63. PubMed ID: 7954259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of c-erbB2 expression in breast cancer.
    Tsutsui S; Ohno S; Murakami S; Hachitanda Y; Oda S
    J Surg Oncol; 2002 Apr; 79(4):216-23. PubMed ID: 11920778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expression of c-erbB2 protein and its relation to prognosis in 284 primary breast cancer patients].
    Yang LF; Song ST; Li XB; Jiang ZF; Liu XQ; Ma WN; Jiao XP; Guo SQ
    Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):294-7. PubMed ID: 16875632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: subanalysis in node-positive and node-negative patients.
    Gasparini G; Toi M; Verderio P; Ranieri G; Dante S; Bonoldi E; Boracchi P; Fanelli M; Tominaga T
    Int J Oncol; 1998 May; 12(5):1117-25. PubMed ID: 9538138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers.
    Sjögren S; Inganäs M; Lindgren A; Holmberg L; Bergh J
    J Clin Oncol; 1998 Feb; 16(2):462-9. PubMed ID: 9469329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of cathepsin D and c-erbB-2 oncoprotein in a subgroup of node-negative breast cancer patients with low histological grade tumors.
    Gaci Z; Bouin-Pineau MH; Gaci M; Daban A; Ingrand P; Métayé T
    Int J Oncol; 2001 Apr; 18(4):793-800. PubMed ID: 11251176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of cytosolic p53 protein in breast cancer.
    Montero S; Guzmán C; Vargas C; Ballestín C; Cortés-Funes H; Colomer R
    Tumour Biol; 2001; 22(5):337-44. PubMed ID: 11553865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of ERBB family mRNA expression in breast carcinomas.
    Bièche I; Onody P; Tozlu S; Driouch K; Vidaud M; Lidereau R
    Int J Cancer; 2003 Sep; 106(5):758-65. PubMed ID: 12866037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical expression of p53 and c-erbB2 proteins in breast cancer in Egypt.
    el-A Helal T; Khalifa A; Kamel AS
    Anticancer Res; 2000; 20(3B):2145-50. PubMed ID: 10928168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma.
    Gasparini G; Weidner N; Bevilacqua P; Maluta S; Dalla Palma P; Caffo O; Barbareschi M; Boracchi P; Marubini E; Pozza F
    J Clin Oncol; 1994 Mar; 12(3):454-66. PubMed ID: 7509851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status.
    Diel IJ; Kaufmann M; Costa SD; Holle R; von Minckwitz G; Solomayer EF; Kaul S; Bastert G
    J Natl Cancer Inst; 1996 Nov; 88(22):1652-8. PubMed ID: 8931609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.
    Järvinen TA; Holli K; Kuukasjärvi T; Isola JJ
    Br J Cancer; 1998 Jun; 77(12):2267-73. PubMed ID: 9649144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple-negative breast cancer types exhibit a distinct poor clinical characteristic in lymph node-negative Chinese patients.
    Liu ZB; Liu GY; Yang WT; Di GH; Lu JS; Shen KW; Shen ZZ; Shao ZM; Wu J
    Oncol Rep; 2008 Oct; 20(4):987-94. PubMed ID: 18813844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study.
    Joensuu H; Isola J; Lundin M; Salminen T; Holli K; Kataja V; Pylkkänen L; Turpeenniemi-Hujanen T; von Smitten K; Lundin J
    Clin Cancer Res; 2003 Mar; 9(3):923-30. PubMed ID: 12631589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of the metastasis-inducing protein S100A4 (p9Ka) in human breast cancer.
    Rudland PS; Platt-Higgins A; Renshaw C; West CR; Winstanley JH; Robertson L; Barraclough R
    Cancer Res; 2000 Mar; 60(6):1595-603. PubMed ID: 10749128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.